A recent study published in Nature by Schade et al. [1] revealed a promising AKT (Protein Kinase B) inhibitor-based therapeutic combination for TNBC (Triple-Negative Breast Cancer). The gene discussed is AKT1; the disease is triple-negative breast carcinoma.